Baillieu Holst
1H17 result: Normalised NPAT (excluding non-recurring items) of A$19.1m (-25% pcp) with normalised revenue of A$59.4m (-15% pcp) and EBITDA of A$33.7 (-16% pcp).
Key takeaways: 1) a relatively weak result was expected and delivered due to strengthening of A$ versus local currencies and reduced visitation to Star Vegas by Thai gamblers after the passing of the King of Thailand; 2) DNA cited recent improvement at Star Vegas in 2H17 with 8.4% pcp increase in rolling turnover in January 2017; 3) strategies to change Aristo’s focus to mass market and reduce win rate volatility appear to be working; 4) 1H17 exhibited very good cost control with the result highlighting high margin nature of operations – 1H17 EBITDA margin of 57% in normalised A$ terms; 5) cash generative nature of operations continues with US$15m in debt repaid in 1H17 and a further A$17.5m repaid in January 2017; and 6) whilst 1H17 profitability at Star Vegas was soft, the overall FY17 result is protected by a vendor guarantee who must make up the shortfall if the property doesn’t attain EBITDA of US$60m – this scenario would also result in DNA not paying the final earn-out, of which the first instalment in FY16 was A$21m.
Outlook: 1) no specific numerical guidance for FY17; 2) DNA expecting usual bias to 2H due to major public holidays in Thailand and China; 3) DNA noting improved visitation in recent weeks at Star Vegas; 4) continued focus at Aristo to attract mass market players; 5) final dividend expected to be declared; and 6) online gaming at Star Vegas scheduled to launch in 4Q17.
Changes to forecasts: We have reduced FY17 and FY18 forecasts by 12% and 9% respectively after considering a weaker 1H17 result than expected, reduced financial footings at Aristo due to lower VIP turnover and updating FX assumptions.
Investment view: BUY retained with High risk rating, revised DCF valuation of A$0.75 (prev. A$0.87) and price target of A$0.75 (prev. A$0.85). Whilst FY17 has started slowly, the decision to focus on less volatile mass and mid-market business has resulted in the desired reduction in risk. The balance sheet is also rapidly improving. It remains hard to identify the catalyst which will re-rate this story. Nonetheless, we retain our BUY call based upon: 1) valuation; 2) the unique high margin status of both properties; 3) the growth available in cross-border gaming in Asia, combined with low tax regimes; and 4) strong cash flows which is now allowing simultaneous debt repayment and dividend payments.
Full report link is below:
https://www.baillieuholst.com.au/publishedresearch/2017/DNA_26feb17.pdf
- Forums
- ASX - By Stock
- Time to buy DNA!
Baillieu Holst 1H17 result: Normalised NPAT (excluding...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DNA (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.53M |
Open | High | Low | Value | Volume |
3.2¢ | 3.2¢ | 3.2¢ | $95 | 2.966K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 93366 | 3.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.4¢ | 118000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 93366 | 0.030 |
1 | 34515 | 0.029 |
3 | 214320 | 0.028 |
3 | 174083 | 0.027 |
1 | 134000 | 0.026 |
Price($) | Vol. | No. |
---|---|---|
0.034 | 118000 | 1 |
0.035 | 583823 | 3 |
0.036 | 196414 | 2 |
0.037 | 236668 | 2 |
0.039 | 36000 | 1 |
Last trade - 15.45pm 27/09/2024 (20 minute delay) ? |
Featured News
DNA (ASX) Chart |